Format

Send to

Choose Destination
See comment in PubMed Commons below
Lancet. 2013 Dec 14;382(9909):1981-92. doi: 10.1016/S0140-6736(13)61615-3. Epub 2013 Sep 3.

Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data.

Author information

1
Université Paris-Diderot, Sorbonne Paris-Cité, Paris, France; Département Hospitalo-Universitaire FIRE, Hôpital Bichat, AP-HP, INSERM U-698, Paris, France. Electronic address: gabriel.steg@bch.aphp.fr.
2
VA Boston Healthcare System, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
3
Kerckhoff Heart Center, Bad Nauheim, Germany.
4
Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY, USA.
5
Beth Israel Deaconess Medical Center, Division of Cardiology, Boston, MA, USA.
6
Duke Clinical Research Institute, Durham, NC, USA.
7
Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
8
The Medicines Company, Parsippany, NJ, USA.
9
Presbyterian Hospital Cardiac Catheterization Laboratory, Charlotte, NC, USA.
10
Moses Cone Heart and Vascular Center, Greensboro, NC, USA.
11
Anaheim Memorial Hospital, Anaheim, CA, USA.
12
Stony Brook University Hospital, Health Sciences Center, Stony Brook, NY, USA.
13
Harbor-UCLA Medical Center, Torrance, CA, USA.
14
Green Lane Cardiovascular Service, Auckland, New Zealand.
15
Stanford University Medical School, Stanford, CA, USA.

Abstract

BACKGROUND:

Cangrelor is a potent, rapid-acting, reversible intravenous platelet inhibitor that was tested for percutaneous coronary intervention (PCI) in three large, double-blind, randomised trials. We did a pooled analysis of data from three trials that assessed the effectiveness of cangrelor against either clopidogrel or placebo in PCI.

METHODS:

This prespecified, pooled analysis of patient-level data from three trials (CHAMPION-PCI, CHAMPION-PLATFORM, and CHAMPION-PHOENIX) compared cangrelor with control (clopidogrel or placebo) for prevention of thrombotic complications during and after PCI. Trial participants were patients undergoing PCI for ST-elevation myocardial infarction (11.6%), non-ST-elevation acute coronary syndromes (57.4%), and stable coronary artery disease (31.0%). Efficacy was assessed in the modified intention-to-treat population of 24,910 patients, with a prespecified primary efficacy composite of death, myocardial infarction, ischaemia-driven revascularisation, or stent thrombosis at 48 h. The primary safety outcome was non-coronary artery bypass graft-related GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) severe or life-threatening bleeding at 48 h.

FINDINGS:

Cangrelor reduced the odds of the primary outcome by 19% (3.8% for cangrelor vs 4.7% for control; odds ratio [OR] 0.81, 95% CI 0.71-0.91, p=0.0007), and stent thrombosis by 41% (0.5% vs 0.8%, OR 0.59, 95% CI 0.43-0.80, p=0.0008). Cangrelor reduced the odds of the secondary triple composite (all-cause death, myocardial infarction, or ischaemia-driven revascularisation at 48 h) by 19% (3.6% vs 4.4%, OR 0.81, 95% CI 0.71-0.92, p=0.0014). Efficacy outcomes were consistent across the trials and main patient subsets. These benefits were maintained at 30 days. There was no difference in the primary safety outcome (0.2% in both groups), in GUSTO moderate bleeding (0.6% vs 0.4%), or in transfusion (0.7% vs 0.6%), but cangrelor increased GUSTO mild bleeding (16.8% vs 13.0%, p<0.0001).

INTERPRETATION:

Compared with control (clopidogrel or placebo), cangrelor reduced PCI periprocedural thrombotic complications, at the expense of increased bleeding.

FUNDING:

The Medicines Company.

PMID:
24011551
DOI:
10.1016/S0140-6736(13)61615-3
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center